Full-Text Search:
Home|Journal Papers|About CNKI|User Service|FAQ|Contact Us|中文
《Chongqing Medicine》 2017-15
Add to Favorite Get Latest Update

A clinical study of Gefitinib retreatment beyond progression in non-small cell lung cancer patients with rare EGFR mutations

Mu Honghao;Qing Yun;Fei Qi;Qiu Dan;Feng Jian;Tu Lingli;Sun Lan;Department of Oncology,People′s Hospital of Bishan District;  
Objective To evaluate the effectiveness and safety of gefitinib retreatment beyond progression(GRBP)in nonsmall cell lung cancer(NSCLC)patients with rare EGFR mutations.Methods We retrospectively analyzed six rare-EGFR-mutation NSCLC patients from Jan 2011 to Dec 2015.Those patients had previous disease control and then disease progression according to Response Evaluation Criteria in Solid Tumors version 1.1(RECIST v1.1)after taking oral gefitinib 250 mg once a day.After that,continuing gefitinib was decided by clinicians′experience at the same treatment option.The primary endpoints were response rate(RR),overall survival(OS),the first and second progression-free survival(PFS-1and PFS-2).Safety was assessed according to the NCI-CTCAE version 4.0.Results After initial treatment of gefitinib,4patients achieved partial response(PR)and 2patients showed stable disease(SD),with RR being 66.7%.The median PFS-1and PFS-2 were 10 months(95%CI 6.6-13.4)and 9months(95%CI6.9-11.1),respectively.The median OS time was 28 months(95%CI 10.4-45.6).The most common treatment-related adverse events were fatigue,diarrhea,rash,itching and elevated transaminases.Conclusion In our study,gefitinib retreatment beyond disease progression is effective with a manageable tolerability profile.
【Fund】: 重庆市卫计委基金项目(20142204);; 重庆市科委项目(cstc2014jcyjA10126)
【CateGory Index】: R734.2
Download(CAJ format) Download(PDF format)
CAJViewer7.0 supports all the CNKI file formats; AdobeReader only supports the PDF format.
【Citations】
Chinese Journal Full-text Database 1 Hits
1 Guo-Hao Xia;Yun Zeng;Ying Fang;Shao-Rong Yu;Li Wang;Mei-Qi Shi;Wei-Li Sun;Xin-En Huang;Jia Chen;Ji- Feng Feng;Department of Medical Oncology, Jiangsu Cancer Hospital;;Effect of EGFR-TKI retreatment following chemotherapy for advanced non-small cell lung cancer patients who underwent EGFR-TKI[J];Cancer Biology & Medicine;2014-04
【Co-citations】
Chinese Journal Full-text Database 2 Hits
1 Mu Honghao;Qing Yun;Fei Qi;Qiu Dan;Feng Jian;Tu Lingli;Sun Lan;Department of Oncology,People′s Hospital of Bishan District;;A clinical study of Gefitinib retreatment beyond progression in non-small cell lung cancer patients with rare EGFR mutations[J];重庆医学;2017-15
2 Hong Chao-yu;Department of Respiratory Medicine,The Fist Affiliated Hospital of Chongqing Medical University;;To Investigate the Efficacy and Safety of Tarceva on 24 Patients with Advanced Non-Small Cell Lung Cancer[J];牡丹江医学院学报;2016-06
【Secondary Citations】
Chinese Journal Full-text Database 3 Hits
1 Chuanhao TANG,Xiaoyan LI,Wanfeng GUO,Jianjie LI,Haifeng QIN,Weixia WANG,Lili QU,Juan AN,Hongjun GAO,Xiaoqing LIU Department of Lung Cancer,Affiliated Hospital of Academy of Military Medical Sciences,Beijing 100071,China;How to Make the Choice in the Retreatment of EGFR-TKI for Advanced NSCLC Patients Who Benefited from Prior Gefitinib Therapy: the Original Drug or Switching to A Second EGFR-TKI?[J];中国肺癌杂志;2013-07
2 Tongtong AN 1,Zhen HUANG 2,Yuyan WANG 1,Zhijie WANG 1,Hua BAI 1,Jie WANG 1 1 Department of oracic Oncology,Beijing Cancer Hospital,Beijing University Oncology College,Beijing 100142,China;2 Department of Osteoma,Beijing Ji Shui Tan Hospital,Beijing 100036,China;Retreatment with Epidermal Growth Factor Receptor Inhibitor After Initial Failure in Advanced Non-small Cell Lung Cancer[J];中国肺癌杂志;2011-03
3 ZHANG Zi-jin,ZHANG Ping,WU Xiao-nan,LI Lin,CHENG Gang Department of Medical Oncology,Beijing Hospital,Beijing 100730,China;Feasibility of Erlotinib after Gefitinib Failure in Patients with Advanced Pulmonary Adenocarcinoma Previously Responding to Gefitinib[J];中国医学科学院学报;2010-04
©2006 Tsinghua Tongfang Knowledge Network Technology Co., Ltd.(Beijing)(TTKN) All rights reserved